Takazawa Yuki, Maeshima Yohei, Kitayama Hiroyuki, Yamamoto Yoshihiko, Kawachi Hiroshi, Shimizu Fujio, Matsui Hideki, Sugiyama Hitoshi, Yamasaki Yasushi, Makino Hirofumi
Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Kidney Int. 2005 Aug;68(2):704-22. doi: 10.1111/j.1523-1755.2005.00449.x.
Although angiotensin II (Ang II) is involved in the progression of renal diseases, infusion of Ang II was reported to surprisingly ameliorate the early phase of anti-Thy-1.1 nephritis. Considering the known proangiogenic effect of Ang II and that angiogenic glomerular capillary repair is required for the recovery of damaged glomeruli in rat anti-Thy-1.1 nephritis, we hypothesized that Ang II infusion starting prior to the initiation of nephritis may induce the expression of angiogenic growth factors such as vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), resulting in the increased glomerular capillary area in the early phase.
Ang II was infused (170 ng/min) in rats, and 5 days later, nephritis was induced by the administration of monoclonal 1-22-3 antibodies. Ang II type 1 or type 2 receptor antagonist (AT(1)R or AT(2)R, respectively) (losartan or PD123319, respectively) was coadministered.
Ang II infusion affected on neither the deposition of Ig nor mesangiolysis in the initial phase, and resulted in the aggravation of creatinine clearance at day 14 and 35 after initiating anti-Thy-1.1 nephritis. Histologic alterations were ameliorated accompanied by reduced loss in rat endothelial cell antigen (RECA)-1(+) endothelial area in Ang II-infused nephritic rats on day 6 and 14 as compared to control nephritic group, and nephritic alterations were mostly resolved on day 35 in both groups. At the early stage (day 6), glomerular expression of VEGF and receptors flk-1 and flt-1 as well as Ang-1, and receptor Tie2 were increased, and glomerular monocyte infiltration and the expression of angiopoietin-2 (Ang-2), a natural antagonist of Ang-1, were reduced. Both Ang II receptors were involved in the regulation of angiogenic factors and receptors.
These results demonstrate that infusion of exogenous Ang II starting prior to the induction of nephritis activates VEGF and Ang-1 signaling regulated via both Ang II receptors, potentially leading to the accelerated recovery of injured glomerular endothelial cells in the early phase of anti-Thy-1.1 nephritis. Increased expression of VEGF and Ang-1 on podocytes further suggests the crucial association of endothelial cells and podocytes in maintaining proper glomerular capillary structures.
尽管血管紧张素II(Ang II)参与肾脏疾病的进展,但据报道,输注Ang II出人意料地改善了抗Thy-1.1肾炎的早期阶段。考虑到已知的Ang II促血管生成作用,以及在大鼠抗Thy-1.1肾炎中受损肾小球的恢复需要血管生成性肾小球毛细血管修复,我们推测在肾炎开始前开始输注Ang II可能会诱导血管内皮生长因子(VEGF)和血管生成素-1(Ang-1)等血管生成生长因子的表达,从而导致早期肾小球毛细血管面积增加。
给大鼠输注Ang II(170 ng/分钟),5天后,通过给予单克隆1-22-3抗体诱导肾炎。同时给予1型或2型血管紧张素II受体拮抗剂(分别为AT(1)R或AT(2)R,即氯沙坦或PD123319)。
输注Ang II在初始阶段既不影响Ig的沉积,也不影响系膜溶解,并且在开始抗Thy-1.1肾炎后第14天和第35天导致肌酐清除率恶化。与对照肾炎组相比,在输注Ang II的肾炎大鼠中,第6天和第14天组织学改变得到改善,同时大鼠内皮细胞抗原(RECA)-1(+)内皮面积的损失减少,两组在第35天肾炎改变大多得到解决。在早期阶段(第6天),VEGF及其受体flk-1和flt-1以及Ang-1及其受体Tie2的肾小球表达增加,肾小球单核细胞浸润以及血管生成素-2(Ang-2,Ang-1的天然拮抗剂)的表达减少。两种血管紧张素II受体均参与血管生成因子及其受体的调节。
这些结果表明,在诱导肾炎前开始输注外源性Ang II可激活通过两种血管紧张素II受体调节的VEGF和Ang-1信号通路,可能导致抗Thy-1.1肾炎早期受损肾小球内皮细胞加速恢复。足细胞上VEGF和Ang-1表达的增加进一步表明内皮细胞和足细胞在维持适当的肾小球毛细血管结构中的关键关联。